Daymark Wealth Partners LLC Takes $988,000 Position in GSK plc (NYSE:GSK)

Daymark Wealth Partners LLC purchased a new stake in shares of GSK plc (NYSE:GSK - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 25,675 shares of the pharmaceutical company's stock, valued at approximately $988,000.

A number of other large investors have also recently made changes to their positions in the stock. JTC Employer Solutions Trustee Ltd boosted its position in GSK by 71.3% in the first quarter. JTC Employer Solutions Trustee Ltd now owns 21,141,012 shares of the pharmaceutical company's stock worth $909,063,000 after purchasing an additional 8,800,822 shares during the last quarter. Fisher Asset Management LLC increased its holdings in GSK by 10.6% during the fourth quarter. Fisher Asset Management LLC now owns 15,036,881 shares of the pharmaceutical company's stock valued at $557,267,000 after buying an additional 1,436,488 shares during the last quarter. Primecap Management Co. CA raised its position in GSK by 13.9% in the second quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company's stock worth $558,689,000 after acquiring an additional 1,773,020 shares during the period. Mondrian Investment Partners LTD boosted its stake in shares of GSK by 37.8% during the 1st quarter. Mondrian Investment Partners LTD now owns 5,510,840 shares of the pharmaceutical company's stock worth $236,250,000 after acquiring an additional 1,512,442 shares during the last quarter. Finally, Equity Investment Corp grew its position in shares of GSK by 1.0% during the 2nd quarter. Equity Investment Corp now owns 3,433,202 shares of the pharmaceutical company's stock valued at $132,178,000 after acquiring an additional 34,631 shares during the period. 15.74% of the stock is currently owned by institutional investors.

GSK Price Performance

NYSE GSK traded down $0.19 during trading hours on Friday, reaching $40.71. The company's stock had a trading volume of 3,137,117 shares, compared to its average volume of 3,564,535. GSK plc has a 1 year low of $33.67 and a 1 year high of $45.92. The company has a quick ratio of 0.54, a current ratio of 0.82 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $84.37 billion, a price-to-earnings ratio of 14.75, a PEG ratio of 1.31 and a beta of 0.66. The firm's 50-day moving average price is $41.54 and its 200-day moving average price is $41.62.

GSK (NYSE:GSK - Get Free Report) last released its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. GSK had a net margin of 12.87% and a return on equity of 51.48%. The firm had revenue of $9.95 billion for the quarter, compared to the consensus estimate of $9.49 billion. On average, equities research analysts predict that GSK plc will post 4.17 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 10th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.3843 per share. This represents a $1.54 annualized dividend and a dividend yield of 3.78%. The ex-dividend date is Friday, August 16th. This is an increase from GSK's previous quarterly dividend of $0.38. GSK's dividend payout ratio is 54.71%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Barclays raised GSK to a "hold" rating in a report on Tuesday, August 27th. Argus raised GSK to a "strong-buy" rating in a research report on Wednesday, August 7th. Citigroup raised shares of GSK to a "strong-buy" rating in a report on Monday, June 24th. Berenberg Bank raised shares of GSK to a "strong-buy" rating in a report on Thursday, June 20th. Finally, Jefferies Financial Group increased their price objective on shares of GSK from $52.50 to $53.00 and gave the stock a "buy" rating in a research note on Tuesday, July 2nd. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.